Related references
Note: Only part of the references are listed.Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients
Denis Migliorini et al.
NEURO-ONCOLOGY (2019)
Actively personalized vaccination trial for newly diagnosed glioblastoma
Norbert Hilf et al.
NATURE (2019)
Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study
D. Gramatzki et al.
ANNALS OF ONCOLOGY (2018)
Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients
J. N. Jakobsen et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Concepts for Immunotherapies in Gliomas
Michael Platten et al.
SEMINARS IN NEUROLOGY (2018)
Combinations of Bevacizumab With Cancer Immunotherapy
Daniel S. Chen et al.
CANCER JOURNAL (2018)
Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients
David A. Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival.
David M. Peereboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Primary brain tumours in adults
Sarah Lapointe et al.
LANCET (2018)
Treatment of glioblastoma in adults
Wolfgang Wick et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2018)
Improving immune-vascular crosstalk for cancer immunotherapy
Yuhui Huang et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma A Randomized Clinical Trial
Roger Stupp et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Lucia Nogova et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
Lin Tian et al.
NATURE (2017)
ATIM-18. A PHASE I TRIAL OF HYPOFRACTIONATED STEREOTACTIC IRRADIATION (HFSRT) WITH PEMBROLIZUMAB AND BEVACIZUMAB IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA (NCT02313272)
Solmaz Sahebjam et al.
NEURO-ONCOLOGY (2017)
Lomustine and Bevacizumab in Progressive Glioblastoma
Wolfgang Wick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine
D. H. Heiland et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma
Roy Rampling et al.
CLINICAL CANCER RESEARCH (2016)
Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?
Valerie Dutoit et al.
FRONTIERS IN ONCOLOGY (2016)
PD-1 blockade enhances the vaccination-induced immune response in glioma
Joseph P. Antonios et al.
JCI INSIGHT (2016)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
IMCT-08ReACT: LONG-TERM SURVIVAL FROM A RANDOMIZED PHASE II STUDY OF RINDOPEPIMUT (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA
David A. Reardon et al.
NEURO-ONCOLOGY (2015)
Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data
Patrick A. Ott et al.
FRONTIERS IN ONCOLOGY (2015)
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
Walter Taal et al.
LANCET ONCOLOGY (2014)
Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
CANCER IMMUNOLOGY RESEARCH (2014)
VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
Magali Terme et al.
CANCER RESEARCH (2013)
Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trials of Antiangiogenic Therapy
Olivier L. Chinot et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2013)
Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival
Christina Chen et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy
Valerie Dutoit et al.
BRAIN (2012)
The anatomical and cellular basis of immune surveillance in the central nervous system
Richard M. Ransohoff et al.
NATURE REVIEWS IMMUNOLOGY (2012)
VALIDATION AND SIMPLIFICATION OF THE RADIATION THERAPY ONCOLOGY GROUP RECURSIVE PARTITIONING ANALYSIS CLASSIFICATION FOR GLIOBLASTOMA
Jing Li et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Clinical trial end points for high-grade glioma: the evolving landscape
David A. Reardon et al.
NEURO-ONCOLOGY (2011)
Bevacizumab and Recurrent Malignant Gliomas: A European Perspective
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Tumour angiogenesis: Its mechanism and therapeutic implications in malignant gliomas
Michael L. H. Wong et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses
Ingo Fricke et al.
CLINICAL CANCER RESEARCH (2007)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors
RT Tong et al.
CANCER RESEARCH (2004)
VEGF as a Mediator of tumor-associated immunodeficiency
JE Ohm et al.
IMMUNOLOGIC RESEARCH (2001)
Share Paper
